In recent years, the resurgence of interest in psychedelic substances has spotlighted psilocybin as a potential breakthrough in mental health treatment.
Psilocybin significantly reduced the frequency and severity of cluster headaches, with participants experiencing approximately a 50% decrease in weekly attacks and improvements in pain severity and medication use.
The psychedelic substance known as psilocybin initially increases then decreases neural responsiveness to sound in the mouse auditory cortex while enhancing functional connectivity.
Psilocybin, found in magic mushrooms, increases brain connectivity, leading to profound changes in perception and feelings of unity, helping explain mystical experiences and its potential for treating mental health disorders.
Psilocybin, found in "magic mushrooms," does not impair learning and may enhance exploration. Higher doses improved learning rates, especially with certain cues, suggesting potential cognitive benefits in therapeutic settings.
Recent findings suggest that cannabis and psilocybin may benefit those experiencing chronic pain.
A 41-year-old woman with Long-COVID reportedly experienced significant symptom relief after using psilocybin and MDMA, but the effectiveness and safety of these psychedelics for Long-COVID remain uncertain and require further research.
A new study found that psilocybin improves body weight maintenance and cognitive flexibility in female rats modeled for anorexia nervosa, mainly through serotonin 5-HT1A receptor activity. These effects suggest potential therapeutic benefits for treating cognitive inflexibility in anorexia.
A pilot study found that psilocybin administered in a group retreat setting led to enhanced psychological flexibility, improved self-compassion, and reduced cognitive fusion, suggesting potential therapeutic benefits for mental health.
Combining psilocybin with meditation enhances brain connectivity and information flow, according to new research. This was evidenced by increased centrality in brain networks, suggesting improved cognitive integration.
New research shows psilocybin causes anxiety in mice through mechanisms distinct from its psychedelic effects. While ketanserin reduces psilocybin’s psychedelic impact by targeting the 5-HT2A receptor, it does not alleviate the anxiety, suggesting different pathways are involved.
New research suggests psilocybin-assisted therapy can lead to both short-term and long-term negative effects, including emotional and cognitive instability, difficulties in therapist-client relationships, and challenges integrating therapy insights, indicating the need for cautious application and further research into its psychological...
Researchers at the University of Michigan found that psilocybin significantly reduced chronic touch-related pain in rats without affecting heat-related pain. The pain relief outlasted the drug's presence in the body, suggesting a central brain mechanism could be responsible.
Researchers recently explored the potential of psilocybin, a compound from magic mushrooms, to combat diabetes. The findings suggest that psilocybin might protect pancreatic β-cells from damage.
A pivotal study explored how patient expectations affect psilocybin therapy outcomes, discovering no significant impact. Interestingly, suggestible individuals showed enhanced benefits, suggesting a unique interplay between mindset and psychedelic therapy effectiveness.